IGHE and allergic disease: Indeed, since allergen-specific immunotherapy can be hazardous due to difficulties in predicting specific IgE-mediated side effects, reduced form of GRP, devoid of IgE reactivity, could be safely used in specific allergen immunotherapy protocols as previously proposed for pollen and house dust mite allergy as soon as 1998 [reviewed in (23)].